Centerpoint Advisors’s AstraZeneca AZN Stock Holding History

Centerpoint Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-450	Closed	-$89K	–	401
2026 Q1	$89K	Hold	450	–	–	0.03%	122
2025 Q4	$83K	Hold	450	–	–	0.03%	132
2025 Q3	$69K	Hold	450	–	–	0.02%	146
2025 Q2	$63K	Hold	450	–	–	0.02%	144
2025 Q1	$66K	Hold	450	–	–	0.02%	146
2024 Q4	$59K	Hold	450	–	–	0.02%	157
2024 Q3	$70K	Hold	450	–	–	0.02%	149
2024 Q2	$70K	Buy	450 +390	+650%	+$58.7K	0.03%	151
2024 Q1	$8K	Hold	60	–	–	﹤0.01%	334
2023 Q4	$8K	Sell	60 -85	-59%	-$11.1K	﹤0.01%	334
2023 Q3	$20K	Hold	145	–	–	0.01%	223
2023 Q2	$21K	Sell	145 -168	-54%	-$24.7K	0.01%	235
2023 Q1	$43K	Buy	+313	New	+$42.1K	0.02%	173
2022 Q3	–	Sell	-5	Closed	-$1K	–	386
2022 Q2	$1K	Hold	5	–	–	﹤0.01%	340
2022 Q1	$1K	Hold	5	–	–	﹤0.01%	348
2021 Q4	$1K	Buy	+5	New	+$588	﹤0.01%	361
2018 Q3	–	Sell	-282	Closed	-$20K	–	247
2018 Q2	$20K	Buy	+282	New	+$20.3K	0.02%	140

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Centerpoint Advisors's AZN Position: Q2 2026 in Review

Centerpoint Advisors sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 450 shares — an estimated $89K sold.

Centerpoint Advisors first reported a position in AZN in Q2 2018 and held it in 17 quarters. The position peaked at $89K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Centerpoint Advisors reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
Centerpoint Advisors sold 450 AstraZeneca shares in Q2 2026, an estimated $89K.
Centerpoint Advisors first reported a position in AstraZeneca in Q2 2018 and held it in 17 quarters.
Centerpoint Advisors's AstraZeneca position peaked at $89K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Centerpoint Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.